AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00946920
Drug: Goserelin acetate
RxNorm normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The goserelin doses were administered by subcutaneous (s.c.) implants into the abdominal wall. An initial dose of 3.6 mg goserelin was administered on Day 0. One month later a subsequent dose of 10.8 mg was administered and this was repeated after 4, 7, and 10 months (ie a total of 5 implants).
Trial: NCT01790087
Drug: ANX-188 Supratherapeutic dose
RxNorm normalized name: hydroxyzine hydrochloride Oral Tablet [Anx]
DrugBank: Hydroxyzine (DB00557)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01790087
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01790087
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02833987
Drug: Apixaban (ATC B01AF02)
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Exposure to apixaban (ATC B01AF02) will be defined as a new prescription for apixaban in the 30 days following the date of an incident VTE diagnosis.
Trial: NCT02833987
Drug: Dabigatran (ATC B01AE07)
DrugBank: Dabigatran (DB14726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure to dabigatran (ATC B01AE07) will be defined as a new prescription for dabigatran in the 30 days following the date of an incident VTE diagnosis.
Trial: NCT02833987
Drug: Rivaroxaban (ATC B01AF01)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Exposure to rivaroxaban (ATC B01AF01) will be defined as a new prescription for rivaroxaban in the 30 days following the date of an incident VTE diagnosis.
Trial: NCT02833987
Drug: Warfarin (ATC B01AA03)
RxNorm normalized name: (-)-Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exposure to warfarin (ATC B01AA03) will be defined as a new prescription for warfarin in the 30 days following the date of an incident VTE diagnosis.
Trial: NCT00102752
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00981487
Drug: Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24 mg one time
Trial: NCT00981487
Drug: Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24 mg, on time in the am
Trial: NCT01154231
Drug: Nonacog Alfa (Genetical Recombination)
RxNorm normalized name: nonacog alfa
DrugBank: Coagulation Factor IX (Recombinant) (DB00100)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Patients with hemophilia B (congenital blood coagulation factor IX deficiency) who are administered this drug.~Patients with hemophilia B are either patients for whom treatment was already started with a blood coagulation factor IX product (Previously treated patients: hereinafter, PTPs) or patients who have no history of treatment with a blood coagulation factor IX product in the past and for whom treatment will be started with this drug for the first time (Previously untreated patients: hereinafter, PUPs).~The definition of PUPs in this survey is Patients in whom the total number of days of administration of a blood coagulation factor IX product other than this drug before administration of this drug was 3 exposure days (actual number of days of administration: hereinafter, EDs) or less.
Trial: NCT01597973
Drug: colistin and meropenem
RxNorm normalized name: meropenem and vaborbactam
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: colistin standard loading dose, maintenance dose based on patients renal function meropenem- dose based on patients renal function
Trial: NCT01597973
Drug: colistin and placebo
DrugBank: Colistin (DB00803)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: colistin- loading dose standard, maintenance dosed based on patients renal function placebo- mimic meropenem (blinded)
Trial: NCT01565889
Drug: EFV
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efavirenz (EFV) 600 mg tablet administered orally once daily
Trial: NCT01565889
Drug: ATV
RxNorm normalized name: PrenatVite Tablet
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atazanavir (ATV) 400 mg tablet administered orally once daily
Trial: NCT01565889
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir (RTV) 100 mg tablet administered orally once daily
Trial: NCT01565889
Drug: RAL
RxNorm normalized name: Paral
DrugBank: Paraldehyde (DB09117)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir (RAL) 400 mg administered administered orally twice daily
Trial: NCT01565889
Drug: PEG
RxNorm normalized name: PEG
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated interferon alfa (PEG) 180 μg administered once weekly by subcutaneous injection
Trial: NCT01565889
Drug: RBV
RxNorm normalized name: RBV
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
Trial: NCT01414673
Drug: HCG
RxNorm normalized name: HCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5000 IU
Trial: NCT02737774
Drug: Icotinib
RxNorm normalized name: icotinib
DrugBank: Icotinib (DB11737)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All cases that meet the criteria take Icotinib for 18 weeks, If there is no disease progression, then after 14 days of washout period, received 4 cycles of pemetrexed / carboplatin. After the chemotherapy, continue with Icotinib, 125mg Tid，PO. until disease progression.
Trial: NCT02737774
Drug: Pemetrexed/Carboplatin
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: All cases that meet the criteria take Icotinib for 18 weeks, If there is no disease progression, then after 14 days of washout period, received 4 cycles of pemetrexed / carboplatin (standard solution, 3 weeks for a cycle of chemotherapy : pemetrexed 500mg/m2 iv , 4 cycles. carboplatin AUC=5 iv ,4 cycles.). After the chemotherapy, continue with Icotinib, 125mg Tid，PO. until disease progression.
Trial: NCT00333294
Drug: Gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00333294
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00333294
Drug: Vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01956201
Drug: Atorvastatin 20mg
RxNorm normalized name: AMLODIPINE 5MG/ATORVASTATIN 20MG TAB
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: \[Atorvastatin Run-in Period\] Take Atorvastatin 20mg 1 tablet once a day (after breakfast) \[Treatment Period\] Take Atrovastatin 20mg/Fenofibrate 160mg or Atorvastiatin 20mg/Placebo of Finofibrate 160mg 2 tablet once a day (after breakfast) \[Extension Period\] Take Atrovastatin 20mg, Fenofibrate 160mg 2 tablet once a day (after breakfast)
Trial: NCT01956201
Drug: Fenofibrate 160mg
RxNorm normalized name: FENOFIBRATE 160MG TAB
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Refer to Intervention Description of Atorvastatin 20mg
Trial: NCT00254709
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00763633
Drug: vitamin B6
RxNorm normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: high dose of vitamin B6
Trial: NCT00763633
Drug: vitamin B6
RxNorm normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: low vitamin B6
Trial: NCT02102854
Drug: rATG
RxNorm normalized name: rATG
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of horse or rabbit-derived antibodies against human T cells, used to prevent \& treat acute rejection in organ transplantation
Trial: NCT02524847
Drug: Methoxsalen
RxNorm normalized name: Methoxsalen
DrugBank: Methoxsalen (DB00553)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sterile solution used in conjunction with photopheresis procedure.
Trial: NCT00810147
Drug: BMS-708163
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsules, Oral, 25 mg, once daily, 24 weeks
Trial: NCT00810147
Drug: BMS-708163
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsules, Oral, 50 mg, once daily, 24 weeks
Trial: NCT00810147
Drug: BMS-708163
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsules, Oral, 100 mg, once daily, 24 weeks
Trial: NCT00810147
Drug: BMS-708163
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsules, Oral, 125 mg, once daily, 24 weeks
Trial: NCT03248427
Drug: Ribociclib
RxNorm normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ribociclib flat-fixed dose of 600 mg daily (three 200-mg capsules), days 1 to 21 of a 28-days cycle.
Trial: NCT03248427
Drug: Letrozole 2.5mg
RxNorm normalized name: LETROZOLE 2.5MG TAB
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily continuous
Trial: NCT03248427
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 80 mg/m2, in one hour IV infusion
Trial: NCT01254773
Drug: Experimental Bapineuzumab
RxNorm normalized name: Bapineuzumab
DrugBank: Bapineuzumab (DB11715)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bapineuzumab 2 mg, Bapineuzumab 7 mg, Bapineuzumab 20 mg, Placebo
Trial: NCT04352101
Drug: Bupropion XL
RxNorm normalized name: Bupropion Hydrochloride 150 MG Oral Tablet, Extended Release [BUPROPION XL]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will take 150 milligrams per day (mg/d) of bupropion XL for two weeks, then the dose will be increased to 300mg/d, as tolerated, for the remaining 6 weeks of the study.
Trial: NCT04352101
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will take 10mg/d of escitalopram for two weeks, then the dose will be increased to 20mg/d, as tolerated, for the remaining 6 weeks of the study.
Trial: NCT00625820
Drug: 6R BH4
RxNorm normalized name: 6R-BH4
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 400 mg 6R BH4 oral BID for 6 weeks then 400 mg of 6R BH4 for another 6 weeks in all arms
Trial: NCT00982657
Drug: CVX-060 + sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: CVX-060 weekly infusions at 6.0 mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
Trial: NCT00982657
Drug: CVX-060 + sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: CVX-060 weekly infusions at 12.0 mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
Trial: NCT00982657
Drug: CVX-060 + sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: CVX-060 weekly infusions at 15.0 mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
Trial: NCT00982657
Drug: CVX-060 + sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: CVX-060 weekly infusions at TBD mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
Trial: NCT00982657
Drug: Sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 50 mg sunitinib daily (4 out of 6 weeks)
Trial: NCT02120638
Drug: Pyrazinamide containing regimen
RxNorm normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, \>70kg 2000-2500mg daily Amikacin 600mg daily Levofloxacin 33-70kg 750 mg daily, \>70kg 1000 mg daily Clarithromycin 33-50kg 500 mg daily, \>50kg 1000 mg daily Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily All treatment is taken daily, for a duration of up to 12 months depending on treatment arm.
Trial: NCT02120638
Drug: Regimen without Pyrazinamide
RxNorm normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid 600mg daily Amikacin 600mg daily Levofloxacin 33-70kg 750 mg daily, \>70kg 1000 mg daily Clarithromycin 33-50kg 500 mg daily, \>50kg 1000 mg daily Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily All treatment is taken daily, for a duration of up to 18 months depending on treatment arm.
Trial: NCT02125500
Drug: Sofosbuvir/Ledipasvir fixed dose
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: SOF 400 mg/LDV 90 mg FDC tablet administered orally once daily
Trial: NCT00610428
Drug: Staccato Prochlorperazine 5 mg
RxNorm normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled Prochlorperazine 5 mg
Trial: NCT00610428
Drug: Staccato Prochlorperazine 10 mg
RxNorm normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled Prochlorperazine10 mg
Trial: NCT01582776
Drug: Lenalidomide and GA101
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1000mg of GA101 on D8, D15 and D22of cycle 1 and on D1 of cycles 2 to 6. Oral lenalidomide once daily at 10/15/20/25mg (phase I part) or at recommended dose (phase II part) on days 1 to 21 of a 28-day cycle for the first cycle and on days 2 to 22 of a 28-day cycle for cycles 2 to 6.
Trial: NCT00349973
Drug: Dipyridamole
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Week 1- 50 mg bid Week 2- 50 mg am and 100 mg pm Weeks 3-6 100 mg am and 100 mg pm
Trial: NCT02565680
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Xyzall 5mg during 5 days + prednisone 40mg during 4 days
Trial: NCT03591874
Drug: Brimonidine Tartrate
RxNorm normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brimonidine Tartrate Nanoemulsion Eye Drops given 2 times a day for 12 weeks.
Trial: NCT00695344
Drug: everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus 2 times per day, v.o., 2 years treatment.
Trial: NCT00308204
Drug: Raptiva
RxNorm normalized name: Raptiva
DrugBank: Efalizumab (DB00095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: injection
Trial: NCT02477644
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablets, per os, 300 mg twice daily;
Trial: NCT00127114
Drug: Amantadine
RxNorm normalized name: Amantadine
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01710787
Drug: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 unilateral intranasal sprays per dose
Trial: NCT01710787
Drug: Tetracaine HCl 3%
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 unilateral intranasal sprays per dose
Trial: NCT01467297
Drug: levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: levofloxacin 500 mg once daily for 7 days
Trial: NCT01738347
Drug: Arm 1 - GEH120714 (18F) Injection
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention is to administer GEH120714 (18F) Injection (100-270 Megabecquerel (MBq), single intravenous administration).
Trial: NCT00263354
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03408639
Drug: Vitamin B12 Injection
RxNorm normalized name: vitamin B12 Injectable Solution
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B12 is monthly injected to all the patients.
Trial: NCT03383523
Drug: Emodepside (BAY 44-4400)
RxNorm normalized name: Emodepside
DrugBank: Emodepside (DB11403)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets compared to the liquid formulation
Trial: NCT01983566
Drug: BI 207127 high fat
RxNorm normalized name: Fats, lanolin
DrugBank: Lanolin (DB11112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 207127 as a single dose after a high fat breakfast
Trial: NCT01983566
Drug: BI 207127 with Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BI 207127 as a single dose after 4 days treatment of Omeprazole 40 mg once a day
Trial: NCT01983566
Drug: BI 207127
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 207127 as a single dose in fasted state
Trial: NCT01983566
Drug: BI 207127 low fat
RxNorm normalized name: Fats, lanolin
DrugBank: Lanolin (DB11112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 207127 as a single dose after a low fat breakfast
Trial: NCT03766295
Drug: Masitinib
RxNorm normalized name: masitinib
DrugBank: Masitinib (DB11526)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03766295
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02054052
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 100 mg, intrapleural injection treating MPE after the drainage of MPE
Trial: NCT03182426
Drug: Plerixafor
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic CD34+ stem cell mobilization for beta-cell repair
Trial: NCT03182426
Drug: Alemtuzumab
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: T-cell depletion
Trial: NCT03182426
Drug: Anakinra
RxNorm normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Anti-inflammatory
Trial: NCT03182426
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-inflammatory
Trial: NCT03182426
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Beta-cell regeneration
Trial: NCT04435834
Drug: Propofol or Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient's will be randomized to the group receiving propofol, or the group receiving sevoflurane.
Trial: NCT03515512
Drug: Enasidenib
RxNorm normalized name: Enasidenib
DrugBank: Enasidenib (DB13874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enasidenib may help block the over production of IDH2, which when mutated, can overproduce metabolites and compounds that contribute to the growth of tumors and cancerous cells
Trial: NCT01791309
Drug: combination panitumumab and vemurafenib
RxNorm normalized name: Vemurafenib
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Treatment will consist of panitumumab 6mg/kg IV every 14 days and vemurafenib 960mg orally twice daily. In patients who initially respond to treatment and later progress, a voluntary biopsy will be requested at the time of relapse to study mechanisms of acquired resistance. This biopsy should consist of at least one frozen core specimen. Every effort will be made to obtain this biopsy within 30 days of discontinuation of treatment and before the initiation of any new tumor-directed therapies.
Trial: NCT01591083
Drug: esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden)
RxNorm normalized name: esomeprazole Injection [Nexium]
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis was achieved spontaneously or by gastroscopy. Patients then received a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Then, patients with Rockall score \>=6 are randomized into the double oral dose group and the regular oral dose group. Patients with Rockall score \<6 are assigned to the control group.~In the double oral dose group, patients receive 40 mg oral esomeprazole twice daily for 11 days and followed by 40 mg once daily for 14 days. In the other two groups, patients receive 40 mg oral esomeprazole 40 mg once daily for 25 days.
Trial: NCT02862015
Drug: FOLFIRINOX or Gemcitabine based chemotherapy
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: As a standard palliative chemotherapy, FOLFIRINOX or Gemcitabine based chemotherapy will be treated to the patients.
Trial: NCT00835393
Drug: Pantoprazole Sodium 40 mg delayed-release tablets
RxNorm normalized name: pantoprazole
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 x 40 mg
Trial: NCT03524651
Drug: Ferrous Sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous tartrate (DB13639)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Blisters of 10 capsules containing 150 mg of ferrous sulfate.
Trial: NCT03524651
Drug: Fe-ASP
RxNorm normalized name: Slow-Fe
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Boxes of 10 vials of 15 ml containing 800 mg of Iron protein acetyl aspartate.